{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:39:05Z","timestamp":1792676345585,"version":"4.5.0"},"reference-count":93,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FOR5806"],"award-info":[{"award-number":["FOR5806"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["GRK2727"],"award-info":[{"award-number":["GRK2727"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Molecular Recognition"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Following the rise in resistance to PD\u20101\/PD\u2010L1 immune checkpoint blockade therapy in patients with cancer, the TIGIT\/CD155 axis has emerged as a major focus of current research. Several competitive binding inhibitors, including antibodies and small molecules targeting TIGIT or CD155, have demonstrated efficacy in suppressing tumor growth and metastasis, either in preclinical models or clinical trials. This review summarizes the expression patterns of CD155, TIGIT, and DNAM\u20101 across immune cell subsets, along with the downstream signaling pathways modulated by these interactions. Furthermore, it provides an analysis of predicted binding sites among relevant domains. The article also systematically catalogs current therapeutic strategies targeting the CD155\/TIGIT axis in patients, including novel emerging modalities.<\/jats:p>","DOI":"10.1002\/jmr.70048","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:54:20Z","timestamp":1792673660000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Analysis of\n                    <scp>TIGIT<\/scp>\n                    \/\n                    <scp>CD155<\/scp>\n                    Inhibitors in Cancer: Small Molecules, Antibodies, and Emerging Modalities"],"prefix":"10.1002","volume":"39","author":[{"given":"Yu","family":"Han","sequence":"first","affiliation":[{"name":"Department of Medicine II University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University  Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0470-4584","authenticated-orcid":false,"given":"Dominik","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Medicine II University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University  Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ebert","sequence":"additional","affiliation":[{"name":"Department of Medicine II University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University  Mannheim Germany"},{"name":"DKFZ Hector Cancer Institute at the University Medical Center  Mannheim Germany"},{"name":"Molecular Medicine Partnership Unit EMBL  Heidelberg Germany"},{"name":"Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University  Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4969-5697","authenticated-orcid":false,"given":"Elke","family":"Burgermeister","sequence":"additional","affiliation":[{"name":"Department of Medicine II University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University  Mannheim Germany"},{"name":"Mannheim Institute for Innate Immunoscience (MI3), Medical Faculty Mannheim, Heidelberg University  Mannheim Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"e_1_2_15_2_1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.12688\/f1000research.22877.1","article-title":"Targeting the \u201cPVR\u2010TIGIT Axis\u201d With Immune Checkpoint Therapies","volume":"9","author":"Gorvel L.","year":"2020","journal-title":"F1000Res"},{"key":"e_1_2_15_3_1","doi-asserted-by":"crossref","first-page":"216381","DOI":"10.1016\/j.canlet.2023.216381","article-title":"CD155 and Its Receptors in Cancer Immune Escape and Immunotherapy","volume":"573","author":"Zhou R.","year":"2023","journal-title":"Cancer Letters"},{"issue":"47","key":"e_1_2_15_4_1","doi-asserted-by":"crossref","first-page":"18284","DOI":"10.1073\/pnas.0807848105","article-title":"Crystal Structure of CD155 and Electron Microscopic Studies of Its Complexes With Polioviruses","volume":"105","author":"Zhanga P.","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"14","key":"e_1_2_15_5_1","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1073\/pnas.1120606109","article-title":"Structure of TIGIT Immunoreceptor Bound to Poliovirus Receptor Reveals a Cell\u2013Cell Adhesion and Signaling Mechanism That Requires Cis\u2010Trans Receptor Clustering","volume":"109","author":"Stengel K. F.","year":"2012","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"e_1_2_15_6_1","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1073\/pnas.1815716116","article-title":"Binding Mode of the Side\u2010By\u2010Side Two\u2010IgV Molecule CD226\/DNAM\u20101 to Its Ligand CD155\/Necl\u20105","volume":"116","author":"Wang H.","year":"2019","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"e_1_2_15_7_1","doi-asserted-by":"crossref","first-page":"41.e11","DOI":"10.1016\/j.urolonc.2019.07.006","article-title":"Poliovirus Receptor CD155 Is Up\u2010Regulated in Muscle\u2010Invasive Bladder Cancer and Predicts Poor Prognosis","volume":"38","author":"Zhang J.","year":"2020","journal-title":"Urologic Oncology"},{"issue":"5","key":"e_1_2_15_8_1","first-page":"1099","article-title":"PVR (CD155) Expression as a Potential Prognostic Marker in Multiple Myeloma","volume":"10","author":"Lee B. H.","year":"2022","journal-title":"Biomedicine"},{"issue":"20","key":"e_1_2_15_9_1","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1038\/s41388-025-03322-2","article-title":"Preclinical Application of a CD155 Targeting Chimeric Antigen Receptor T Cell Therapy for Digestive System Cancers","volume":"44","author":"Zhang K.","year":"2025","journal-title":"Oncogene"},{"issue":"7","key":"e_1_2_15_10_1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.ajt.2023.04.007","article-title":"Competitive Binding of CD226\/TIGIT With Poliovirus Receptor Regulates Macrophage Polarization and Is Involved in Vascularized Skin Graft Rejection","volume":"23","author":"Zhang D.","year":"2023","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"e_1_2_15_11_1","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1038\/s41467-023-40755-3","article-title":"TIGIT Can Inhibit T Cell Activation via Ligation\u2010Induced Nanoclusters, Independent of CD226 Co\u2010Stimulation","volume":"14","author":"Worboys J. D.","year":"2023","journal-title":"Nature Communications"},{"issue":"7","key":"e_1_2_15_12_1","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the Checkpoint Receptor TIGIT Prevents NK Cell Exhaustion and Elicits Potent Anti\u2010Tumor Immunity","volume":"19","author":"Zhang Q.","year":"2018","journal-title":"Nature Immunology"},{"issue":"6","key":"e_1_2_15_13_1","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41416-025-03046-w","article-title":"TIGIT Antibody With PVR Competitive Ability Enhances Cancer Immunotherapy and Capable of Eliciting Anti\u2010Tumour Immune Memory","volume":"133","author":"Yu H.","year":"2025","journal-title":"British Journal of Cancer"},{"issue":"5","key":"e_1_2_15_14_1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0092-8674(89)90690-9","article-title":"Cellular Receptor for Poliovirus: Molecular Cloning, Nucleotide Sequence, and Expression of a New Member of the Immunoglobulin Superfamily","volume":"56","author":"Mendelsohn C. L.","year":"1989","journal-title":"Cell"},{"issue":"11","key":"e_1_2_15_15_1","first-page":"5700","article-title":"Heterogeneous Expression of Poliovirus Receptor\u2010Related Proteins in Human Cells and Tissues","volume":"10","author":"Freistadt M. S.","year":"1990","journal-title":"Molecular and Cellular Biology"},{"key":"e_1_2_15_16_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1073\/pnas.97.1.73","article-title":"Three\u2010Dimensional Structure of Poliovirus Receptor Bound to Poliovirus","volume":"97","author":"Belnap D. M.","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"e_1_2_15_17_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1073\/pnas.97.1.79","article-title":"Interaction of the Poliovirus Receptor With Poliovirus","volume":"97","author":"He Y.","year":"2000","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"e_1_2_15_18_1","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1038\/s41467-023-41052-9","article-title":"A Human Monoclonal Antibody Binds Within the Poliovirus Receptor\u2010Binding Site to Neutralize All Three Serotypes","volume":"14","author":"Charnesky A. J.","year":"2023","journal-title":"Nature Communications"},{"issue":"7","key":"e_1_2_15_19_1","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1128\/JVI.03017-15","article-title":"Five of Five VHHs Neutralizing Poliovirus Bind the Receptor\u2010Binding Site","volume":"90","author":"Strauss M.","year":"2016","journal-title":"Journal of Virology"},{"issue":"4720","key":"e_1_2_15_20_1","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1126\/science.2994218","article-title":"Three\u2010Dimensional Structure of Poliovirus at 2.9 A Resolution","volume":"229","author":"Hogle J. M.","year":"1985","journal-title":"Science"},{"issue":"3","key":"e_1_2_15_21_1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF01314281","article-title":"Neutralization of Poliovirus by Polyclonal Antibodies Requires Binding of a Single IgG Molecule Per Virion","volume":"91","author":"Wetz K.","year":"1986","journal-title":"Archives of Virology"},{"issue":"5","key":"e_1_2_15_22_1","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1158\/2159-8290.CD-20-1248","article-title":"Therapeutic Targeting of Checkpoint Receptors Within the DNAM1 Axis","volume":"11","author":"Alteber Z.","year":"2021","journal-title":"Cancer Discovery"},{"issue":"1","key":"e_1_2_15_23_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The Surface Protein TIGIT Suppresses T Cell Activation by Promoting the Generation of Mature Immunoregulatory Dendritic Cells","volume":"10","author":"Yu X.","year":"2009","journal-title":"Nature Immunology"},{"issue":"1","key":"e_1_2_15_24_1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12964-020-00701-y","article-title":"Computer\u2010Aided Design of PVR Mutants With Enhanced Binding Affinity to TIGIT","volume":"19","author":"Zhou X.","year":"2021","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"33","key":"e_1_2_15_25_1","doi-asserted-by":"crossref","first-page":"12534","DOI":"10.1074\/jbc.RA119.009261","article-title":"Structural Basis for the Recognition of Nectin\u2010Like Protein\u20105 by the Human\u2010Activating Immune Receptor, DNAM\u20101","volume":"294","author":"Deuss F. A.","year":"2019","journal-title":"Journal of Biological Chemistry"},{"issue":"6","key":"e_1_2_15_26_1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1074-7613(00)70060-4","article-title":"DNAM\u20101, A Novel Adhesion Molecule Involved in the Cytolytic Function of T Lymphocytes","volume":"4","author":"Shibuya A.","year":"1996","journal-title":"Immunity"},{"issue":"5","key":"e_1_2_15_27_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1074-7613(00)80136-3","article-title":"Physical and Functional Association of LFA\u20101 With DNAM\u20101 Adhesion Molecule","volume":"11","author":"Shibuya K.","year":"1999","journal-title":"Immunity"},{"issue":"1","key":"e_1_2_15_28_1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.celrep.2015.03.006","article-title":"DNAM\u20101 Expression Marks an Alternative Program of NK Cell Maturation","volume":"11","author":"Martinet L.","year":"2015","journal-title":"Cell Reports"},{"issue":"1","key":"e_1_2_15_29_1","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s42003-026-10056-8","article-title":"DNAM\u20101 Mediates NK\u2010Cell Activation and Host\u2010Pathogen Interaction via Direct Binding to Fungal Cell Wall Proteases","volume":"9","author":"Natasha F.","year":"2026","journal-title":"Communications Biology"},{"issue":"1","key":"e_1_2_15_30_1","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1038\/s41467-022-30087-z","article-title":"Candida albicans\n                   Evades NK Cell Elimination via Binding of Agglutinin\u2010Like Sequence Proteins to the Checkpoint Receptor TIGIT","volume":"13","author":"Charpak\u2010Amikam Y.","year":"2022","journal-title":"Nature Communications"},{"issue":"2","key":"e_1_2_15_31_1","doi-asserted-by":"crossref","first-page":"e000957","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in Cancer Immunotherapy","volume":"8","author":"Chauvin J. M.","year":"2020","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"12","key":"e_1_2_15_32_1","doi-asserted-by":"crossref","first-page":"e004794","DOI":"10.1136\/jitc-2022-004794","article-title":"TIGIT Blockade Repolarizes AML\u2010Associated TIGIT(+) M2 Macrophages to an M1 Phenotype and Increases CD47\u2010Mediated Phagocytosis","volume":"10","author":"Brauneck F.","year":"2022","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"e_1_2_15_33_1","doi-asserted-by":"crossref","first-page":"1626367","DOI":"10.3389\/fimmu.2025.1626367","article-title":"Identification of a TIGIT\u2010Expressing CD8(+) T Cell Subset as a Potential Prognostic Biomarker in Colorectal Cancer","volume":"16","author":"Cao S.","year":"2025","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"e_1_2_15_34_1","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12957-022-02810-z","article-title":"High Co\u2010Expression of Immune Checkpoint Receptors PD\u20101, CTLA\u20104, LAG\u20103, TIM\u20103, and TIGIT on Tumor\u2010Infiltrating Lymphocytes in Early\u2010Stage Breast Cancer","volume":"20","author":"Mollavelioglu B.","year":"2022","journal-title":"World Journal of Surgical Oncology"},{"issue":"16","key":"e_1_2_15_35_1","doi-asserted-by":"crossref","first-page":"14597","DOI":"10.1007\/s00432-023-05268-y","article-title":"Integrated Single\u2010Cell and Bulk Sequencing Analyses With Experimental Validation Identify the Prognostic and Immunological Implications of CD226 in Pan\u2010Cancer","volume":"149","author":"Ma P.","year":"2023","journal-title":"Journal of Cancer Research and Clinical Oncology"},{"issue":"4","key":"e_1_2_15_36_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00262-026-04343-w","article-title":"Protein\u2010Level Profiling of TIGIT Axis Components in Human PDAC Reveals Immune\u2010Suppressive Expression Patterns","volume":"75","author":"Quatannens D.","year":"2026","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"12","key":"e_1_2_15_37_1","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/intimm\/dxab085","article-title":"DNAM\u20101 Versus TIGIT: Competitive Roles in Tumor Immunity and Inflammatory Responses","volume":"33","author":"Shibuya A.","year":"2021","journal-title":"International Immunology"},{"issue":"1","key":"e_1_2_15_38_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-025-02301-z","article-title":"Targeting CD155 in Lung Adenocarcinoma: A5 Nanobody\u2010Based Therapeutics for Precision Treatment and Enhanced Drug Delivery","volume":"10","author":"Noh K.","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"1","key":"e_1_2_15_39_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41389-023-00475-1","article-title":"CDK4\/6 Inhibitors and the pRB\u2010E2F1 Axis Suppress PVR and PD\u2010L1 Expression in Triple\u2010Negative Breast Cancer","volume":"12","author":"Shrestha M.","year":"2023","journal-title":"Oncogene"},{"issue":"16","key":"e_1_2_15_40_1","doi-asserted-by":"crossref","first-page":"12958","DOI":"10.3390\/ijms241612958","article-title":"CD155 and Its Receptors as Targets for Cancer Therapy","volume":"24","author":"Paolini R.","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"e_1_2_15_41_1","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1038\/s41467-025-59786-z","article-title":"TIGIT Deficiency Promotes Autoreactive CD4(+) T\u2010Cell Responses Through a Metabolic\u2013Epigenetic Mechanism in Autoimmune Myositis","volume":"16","author":"Lai Y.","year":"2025","journal-title":"Nature Communications"},{"issue":"1","key":"e_1_2_15_42_1","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41467-020-15025-1","article-title":"TIGIT Limits Immune Pathology During Viral Infections","volume":"11","author":"Schorer M.","year":"2020","journal-title":"Nature Communications"},{"issue":"8","key":"e_1_2_15_43_1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-018-0020-8","article-title":"Regulatory Mechanisms in T Cell Receptor Signalling","volume":"18","author":"Gaud G.","year":"2018","journal-title":"Nature Reviews. Immunology"},{"issue":"3","key":"e_1_2_15_44_1","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT\u2010Like Motif of TIGIT Suppresses Granule Polarization and Cytotoxicity of NK Cells","volume":"20","author":"Liu S.","year":"2013","journal-title":"Cell Death and Differentiation"},{"issue":"25","key":"e_1_2_15_45_1","doi-asserted-by":"crossref","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","article-title":"T\u2010Cell Immunoglobulin and ITIM Domain (TIGIT) Receptor\/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon\u2010Gamma Production of Natural Killer Cells via Beta\u2010Arrestin 2\u2010Mediated Negative Signaling","volume":"289","author":"Li M.","year":"2014","journal-title":"Journal of Biological Chemistry"},{"issue":"1","key":"e_1_2_15_46_1","doi-asserted-by":"crossref","first-page":"ltaa004","DOI":"10.1093\/immadv\/ltaa004","article-title":"DNAM1 and TIGIT Balance the T Cell Response, With Low T Cell TIGIT Expression Corresponding to Inflammation in Psoriatic Disease","volume":"1","author":"Jacobs M. E.","year":"2021","journal-title":"Immunotherapy Advances"},{"issue":"18","key":"e_1_2_15_47_1","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.1182\/blood-2010-08-300954","article-title":"DNAM\u20101 Ligand Expression on ag\u2010Stimulated T Lymphocytes Is Mediated by ROS\u2010Dependent Activation of DNA\u2010Damage Response: Relevance for NK\u2010T Cell Interaction","volume":"117","author":"Ardolino M.","year":"2011","journal-title":"Blood"},{"issue":"1","key":"e_1_2_15_48_1","doi-asserted-by":"crossref","first-page":"13592","DOI":"10.1038\/s41598-024-64447-0","article-title":"Aspirin Prevents Colorectal Cancer by Regulating the Abundance of \n                     Enterococcus cecorum\n                   and TIGIT(+)Treg Cells","volume":"14","author":"Yang X.","year":"2024","journal-title":"Scientific Reports"},{"issue":"1","key":"e_1_2_15_49_1","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.imbio.2015.08.003","article-title":"TIGIT Negatively Regulates Inflammation by Altering Macrophage Phenotype","volume":"221","author":"Chen X.","year":"2016","journal-title":"Immunobiology"},{"issue":"18","key":"e_1_2_15_50_1","doi-asserted-by":"crossref","first-page":"e0124022","DOI":"10.1128\/jvi.01240-22","article-title":"A Morbillivirus Infection Shifts DC Maturation Toward a Tolerogenic Phenotype to Suppress T Cell Activation","volume":"96","author":"Rodr\u00edguez\u2010Mart\u00edn D.","year":"2022","journal-title":"Journal of Virology"},{"issue":"3","key":"e_1_2_15_51_1","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.1003081","article-title":"Cutting Edge: TIGIT Has T Cell\u2010Intrinsic Inhibitory Functions","volume":"186","author":"Joller N.","year":"2011","journal-title":"Journal of Immunology"},{"issue":"7","key":"e_1_2_15_52_1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/cbin.10268","article-title":"Tolerogenic Dendritic Cells Suppress Murine Corneal Allograft Rejection by Modulating CD28\/CTLA\u20104 Expression on Regulatory T Cells","volume":"38","author":"Yan F.","year":"2014","journal-title":"Cell Biology International"},{"key":"e_1_2_15_53_1","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive Resistance to Therapeutic PD\u20101 Blockade Is Associated With Upregulation of Alternative Immune Checkpoints","volume":"7","author":"Koyama S.","year":"2016","journal-title":"Nature Communications"},{"issue":"8","key":"e_1_2_15_54_1","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1080\/15548627.2020.1805214","article-title":"LC3B Upregulation by NANOG Promotes Immune Resistance and Stem\u2010Like Property Through Hyperactivation of EGFR Signaling in Immune\u2010Refractory Tumor Cells","volume":"17","author":"Kim S.","year":"2021","journal-title":"Autophagy"},{"issue":"1","key":"e_1_2_15_55_1","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1038\/s41467-023-38318-7","article-title":"TRPV1 Inhibition Overcomes Cisplatin Resistance by Blocking Autophagy\u2010Mediated Hyperactivation of EGFR Signaling Pathway","volume":"14","author":"Oh S. J.","year":"2023","journal-title":"Nature Communications"},{"issue":"1","key":"e_1_2_15_56_1","doi-asserted-by":"crossref","first-page":"20600","DOI":"10.1038\/s41598-025-07120-4","article-title":"TRPV1 Inhibition Sensitizes Tumors to PD\u20101 Blockade by Reversing Resistance to CTL\u2010Mediated Killing","volume":"15","author":"Son M. K.","year":"2025","journal-title":"Scientific Reports"},{"issue":"8","key":"e_1_2_15_57_1","doi-asserted-by":"crossref","first-page":"e1466769","DOI":"10.1080\/2162402X.2018.1466769","article-title":"TIGIT and PD\u20101 Dual Checkpoint Blockade Enhances Antitumor Immunity and Survival in GBM","volume":"7","author":"Hung A. L.","year":"2018","journal-title":"Oncoimmunology"},{"issue":"11","key":"e_1_2_15_58_1","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1001\/jamaoncol.2023.3867","article-title":"Anti\u2010TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a\/1b Nonrandomized Controlled Trial","volume":"9","author":"Kim T. W.","year":"2023","journal-title":"JAMA Oncology"},{"issue":"8004","key":"e_1_2_15_59_1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/s41586-024-07121-9","article-title":"Anti\u2010TIGIT Antibody Improves PD\u2010L1 Blockade Through Myeloid and T(Reg) Cells","volume":"627","author":"Guan X.","year":"2024","journal-title":"Nature"},{"issue":"2","key":"e_1_2_15_60_1","doi-asserted-by":"crossref","first-page":"101184","DOI":"10.1016\/j.esmoop.2023.101184","article-title":"Anti\u2010TIGIT Therapies for Solid Tumors: A Systematic Review","volume":"8","author":"Rousseau A.","year":"2023","journal-title":"ESMO Open"},{"issue":"6","key":"e_1_2_15_61_1","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","article-title":"Tiragolumab Plus Atezolizumab Versus Placebo Plus Atezolizumab as a First\u2010Line Treatment for PD\u2010L1\u2010Selected Non\u2010Small\u2010Cell Lung Cancer (CITYSCAPE): Primary and Follow\u2010Up Analyses of a Randomised, Double\u2010Blind, Phase 2 Study","volume":"23","author":"Cho B. C.","year":"2022","journal-title":"Lancet Oncology"},{"issue":"2","key":"e_1_2_15_62_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.annonc.2021.11.002","article-title":"First\u2010In\u2010Human Phase 1 Study of the Anti\u2010TIGIT Antibody Vibostolimab as Monotherapy or With Pembrolizumab for Advanced Solid Tumors, Including Non\u2010Small\u2010Cell Lung Cancer","volume":"33","author":"Niu J.","year":"2022","journal-title":"Annals of Oncology"},{"issue":"27","key":"e_1_2_15_63_1","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1080\/14796694.2024.2343272","article-title":"The KEYVIBE Program: Vibostolimab and Pembrolizumab for the Treatment of Advanced Malignancies","volume":"20","author":"Shapira\u2010Frommer R.","year":"2024","journal-title":"Future Oncology"},{"issue":"2","key":"e_1_2_15_64_1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/13543776.2020.1709445","article-title":"Cancer Combinatorial Immunotherapy Using Etigilimab and Nivolumab: A Patent Evaluation of WO2018102536","volume":"30","author":"Perez\u2010Santos M.","year":"2020","journal-title":"Expert Opinion on Therapeutic Patents"},{"issue":"1","key":"e_1_2_15_65_1","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1038\/s41467-026-74782-7","article-title":"Anti\u2010PD\u20101 Plus Anti\u2010CTLA\u20104 Blockade Overcomes Immune Exclusion in NSCLC Brain Metastases by Enhancing CD8(+) T Cell Responses and Promoting Tertiary Lymphoid Structure Formation","volume":"17","author":"Hosoya K.","year":"2026","journal-title":"Nature Communications"},{"issue":"11","key":"e_1_2_15_66_1","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","article-title":"The PD\u20101\u2010 and LAG\u20103\u2010Targeting Bispecific Molecule Tebotelimab in Solid Tumors and Hematologic Cancers: A Phase 1 Trial","volume":"29","author":"Luke J. J.","year":"2023","journal-title":"Nature Medicine"},{"key":"e_1_2_15_67_1","doi-asserted-by":"crossref","first-page":"840457","DOI":"10.3389\/fimmu.2022.840457","article-title":"CD226 and TIGIT Cooperate in the Differentiation and Maturation of Human Tfh Cells","volume":"13","author":"Yasutomi M.","year":"2022","journal-title":"Frontiers in Immunology"},{"issue":"40","key":"e_1_2_15_68_1","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1002\/anie.201506225","article-title":"Blocking of the PD\u20101\/PD\u2010L1 Interaction by a D\u2010Peptide Antagonist for Cancer Immunotherapy","volume":"54","author":"Chang H. N.","year":"2015","journal-title":"Angewandte Chemie (International Ed. in English)"},{"issue":"1","key":"e_1_2_15_69_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12964-018-0239-9","article-title":"The Design of High Affinity Human PD\u20101 Mutants by Using Molecular Dynamics Simulations (MD)","volume":"16","author":"Du J.","year":"2018","journal-title":"Cell Communication and Signaling"},{"issue":"35","key":"e_1_2_15_70_1","doi-asserted-by":"crossref","first-page":"15114","DOI":"10.1002\/anie.202002783","article-title":"A Novel d\u2010Peptide Identified by Mirror\u2010Image Phage Display Blocks TIGIT\/PVR for Cancer Immunotherapy","volume":"59","author":"Zhou X.","year":"2020","journal-title":"Angewandte Chemie (International Ed. in English)"},{"issue":"3","key":"e_1_2_15_71_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2174\/1568026619666190308131805","article-title":"Small\u2010Molecule Immuno\u2010Oncology Therapy: Advances, Challenges and New Directions","volume":"19","author":"Chen S.","year":"2019","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"5","key":"e_1_2_15_72_1","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s11427-023-2472-4","article-title":"Hemin Blocks TIGIT\/PVR Interaction and Induces Ferroptosis to Elicit Synergistic Effects of Cancer Immunotherapy","volume":"67","author":"Zhou X.","year":"2024","journal-title":"Science China. Life Sciences"},{"key":"e_1_2_15_73_1","doi-asserted-by":"crossref","first-page":"116162","DOI":"10.1016\/j.bcp.2024.116162","article-title":"Dual Targeting of TIGIT and PD\u20101 With a Novel Small Molecule for Cancer Immunotherapy","volume":"223","author":"Li Y.","year":"2024","journal-title":"Biochemical Pharmacology"},{"issue":"1","key":"e_1_2_15_74_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s13045-022-01352-x","article-title":"Elraglusib (9\u2010ING\u201041), a Selective Small\u2010Molecule Inhibitor of Glycogen Synthase Kinase\u20103 Beta, Reduces Expression of Immune Checkpoint Molecules PD\u20101, TIGIT and LAG\u20103 and Enhances CD8(+) T Cell Cytolytic Killing of Melanoma Cells","volume":"15","author":"Shaw G.","year":"2022","journal-title":"Journal of Hematology & Oncology"},{"issue":"1","key":"e_1_2_15_75_1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/jpm14010068","article-title":"Inhibitors of Immune Checkpoints: Small Molecule\u2010 and Peptide\u2010Based Approaches","volume":"14","author":"Fuchs N.","year":"2024","journal-title":"Journal of Personalized Medicine"},{"issue":"16","key":"e_1_2_15_76_1","doi-asserted-by":"crossref","first-page":"9050","DOI":"10.1200\/JCO.2023.41.16_suppl.9050","article-title":"Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of AZD2936, a Bispecific Antibody Targeting PD\u20101 and TIGIT, in Checkpoint Inhibitor (CPI)\u2010Experienced Advanced\/Metastatic Non\u2010Small\u2010Cell Lung Cancer (NSCLC): First Report of ARTEMIDE\u201001","volume":"41","author":"Rohrberg K. S.","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_15_77_1","doi-asserted-by":"publisher","DOI":"10.1101\/2023.05.11.540461"},{"issue":"16","key":"e_1_2_15_78_1","doi-asserted-by":"crossref","first-page":"e14504","DOI":"10.1200\/JCO.2024.42.16_suppl.e14504","article-title":"A Phase I\/II, Open\u2010Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Patients With Advanced Solid Tumors","volume":"42","author":"Sun Y.","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_15_79_1","doi-asserted-by":"crossref","first-page":"18011","DOI":"10.1038\/s41598-022-22975-7","article-title":"Development of a Bispecific Antibody Targeting PD\u2010L1 and TIGIT With Optimal Cytotoxicity","volume":"12","author":"Zhong Z.","year":"2022","journal-title":"Scientific Reports"},{"key":"e_1_2_15_80_1","doi-asserted-by":"crossref","first-page":"100467","DOI":"10.1016\/j.ctarc.2021.100467","article-title":"Discovery of a Novel Anti PD\u2010L1 X TIGIT Bispecific Antibody for the Treatment of Solid Tumors","volume":"29","author":"Xiao Y.","year":"2021","journal-title":"Cancer Treatment and Research Communications"},{"issue":"5","key":"e_1_2_15_81_1","doi-asserted-by":"crossref","first-page":"e754","DOI":"10.1002\/ctm2.754","article-title":"PD\u2010L1\/TIGIT Bispecific Antibody Showed Survival Advantage in Animal Model","volume":"12","author":"Mu S.","year":"2022","journal-title":"Clinical and Translational Medicine"},{"issue":"1","key":"e_1_2_15_82_1","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT Is the Central Player in T\u2010Cell Suppression Associated With CAR T\u2010Cell Relapse in Mantle Cell Lymphoma","volume":"21","author":"Jiang V. C.","year":"2022","journal-title":"Molecular Cancer"},{"issue":"1","key":"e_1_2_15_83_1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13073-025-01490-0","article-title":"Pan\u2010Cancer Analysis Identifies CD155 as a Promising Target for CAR\u2010T Cell Therapy","volume":"17","author":"Liu X.","year":"2025","journal-title":"Genome Medicine"},{"issue":"2","key":"e_1_2_15_84_1","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","article-title":"PD\u20101 and TIGIT Downregulation Distinctly Affect the Effector and Early Memory Phenotypes of CD19\u2010Targeting CAR T Cells","volume":"30","author":"Lee Y. H.","year":"2022","journal-title":"Molecular Therapy"},{"issue":"10","key":"e_1_2_15_85_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/protein\/gzw040","article-title":"Novel Human IgG1 and IgG4 Fc\u2010Engineered Antibodies With Completely Abolished Immune Effector Functions","volume":"29","author":"Schlothauer T.","year":"2016","journal-title":"Protein Engineering, Design & Selection"},{"issue":"1","key":"e_1_2_15_86_1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-024-03411-x","article-title":"Neoadjuvant Anti\u2010PD\u20101 Alone or in Combination With Anti\u2010TIGIT or an Oncolytic Virus in Resectable Stage IIIB\u2010D Melanoma: A Phase 1\/2 Trial","volume":"31","author":"Dummer R.","year":"2025","journal-title":"Nature Medicine"},{"issue":"25","key":"e_1_2_15_87_1","first-page":"2400","article-title":"SKYSCRAPER\u201001: A Phase III, Randomized Trial of Tiragolumab (Tira)\u2009+\u2009Atezolizumab (Atezo) Versus Placebo (Pbo)\u2009+\u2009Atezo in Patients (Pts) With Previously\u2010Untreated PD\u2010L1\u2010High, Locally Advanced Unresectable\/Metastatic NSCLC","volume":"44","author":"Peters S. H.","year":"2025","journal-title":"Cancer Research"},{"issue":"3","key":"e_1_2_15_88_1","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.23.01363","article-title":"SKYSCRAPER\u201002: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive\u2010Stage Small\u2010Cell Lung Cancer","volume":"42","author":"Rudin C. M.","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"e_1_2_15_89_1","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41419-025-07984-4","article-title":"TIGIT in Cancer: From Mechanism of Action to Promising Immunotherapeutic Strategies","volume":"16","author":"Cui H.","year":"2025","journal-title":"Cell Death & Disease"},{"issue":"12","key":"e_1_2_15_90_1","first-page":"100937","article-title":"Beyond TIGIT: Lessons From a Failed Immune Checkpoint for Rational Target Discovery","volume":"6","author":"Ding J.","year":"2025","journal-title":"Medicus"},{"issue":"1","key":"e_1_2_15_91_1","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small Molecules in Targeted Cancer Therapy: Advances, Challenges, and Future Perspectives","volume":"6","author":"Zhong L.","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"4","key":"e_1_2_15_92_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","article-title":"The Present and Future of Bispecific Antibodies for Cancer Therapy","volume":"23","author":"Klein C.","year":"2024","journal-title":"Nature Reviews. Drug Discovery"},{"key":"e_1_2_15_93_1","unstructured":"ClinicalTrials.gov \u201cA Study of AZD2936 Anti\u2010TIGIT\/Anti\u2010PD\u20101 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE\u201001) \u201d2021 available from: NCT04995523."},{"key":"e_1_2_15_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2010026\u201001322\u20101"}],"container-title":["Journal of Molecular Recognition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmr.70048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jmr.70048","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmr.70048","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:54:32Z","timestamp":1792673672000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmr.70048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1002\/jmr.70048"],"URL":"https:\/\/doi.org\/10.1002\/jmr.70048","archive":["Portico"],"relation":{},"ISSN":["0952-3499","1099-1352"],"issn-type":[{"value":"0952-3499","type":"print"},{"value":"1099-1352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"2026-02-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70048"}}